RXST
What one share of RxSight holds
Ophthalmic Goods
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system (“RxSight system”) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery.
RxSight’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.09 |
|---|---|
| Profit | −$1.14 |
| Capex (buildings and equipment) | $0.11 |
| Free cash flow | −$0.66 |
| Cash and investments | $0.32 |
| Book value | $6.33 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $1.66 | −$3.57 | $0.14 | −$3.42 | — | — |
| 2022 | $1.77 | −$2.41 | $0.09 | −$2.21 | — | $3.18 |
| 2023 | $2.59 | −$1.41 | $0.14 | −$1.35 | — | $4.44 |
| 2024 | $3.60 | −$0.71 | $0.14 | −$0.58 | — | $6.96 |
| 2025 | $3.29 | −$0.95 | $0.09 | −$0.47 | — | $6.68 |